Praluent Cost in District of Columbia 2026: Prices, Coverage, and Savings Options

What Is Praluent and Why Does It Cost So Much?

Praluent is a fully human monoclonal antibody that inhibits PCSK9, the protein that degrades LDL receptors on hepatocytes. Blocking PCSK9 keeps more receptors on the liver surface, pulling more LDL-C out of circulation. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD requiring additional LDL lowering beyond what a maximally tolerated statin provides [1]. The drug is administered as a subcutaneous injection every two weeks, either 75 mg or 150 mg depending on LDL response.

The price reflects the cost of biologic manufacturing. Unlike small-molecule pills, monoclonal antibodies require mammalian cell culture, extensive purification, and cold-chain logistics. Regeneron and Sanofi set the wholesale acquisition cost (WAC) at approximately $580 per month for both dose strengths in 2026. That figure has remained relatively stable since the pair reduced the list price from over $14,000 per year to roughly $5,850 annually in 2018 following payer pressure and the ODYSSEY OUTCOMES cardiovascular outcomes data [2].

The FDA label specifies that clinicians should assess LDL-C at four to eight weeks after initiation to determine whether dose titration from 75 mg to 150 mg is needed [1]. Both dose levels carry the same list price, which simplifies cost modeling for patients who end up on the higher dose.

LDL-lowering with PCSK9 inhibition is not modest. A 2019 Cochrane review of alirocumab trials (19 RCTs, N=12,666) found a mean LDL-C reduction of 54.0% versus placebo when added to background statin therapy [3]. That magnitude of reduction matters when calculating cardiovascular risk reduction and justifying insurer expenditure.

ODYSSEY OUTCOMES: The Trial That Defines Medical Necessity

ODYSSEY OUTCOMES enrolled 18,924 patients with acute coronary syndrome in the prior one to twelve months and randomized them to alirocumab 75-150 mg Q2W or placebo on top of high-intensity statins [2]. Over a median follow-up of 2.8 years, alirocumab reduced the primary composite endpoint (coronary heart disease death, nonfatal MI, ischemic stroke, or unstable angina requiring hospitalization) by 15% versus placebo (hazard ratio 0.85 to 95% CI 0.78-0.93, P<0.001) [2].

All-cause mortality showed a directional benefit (HR 0.85 to 95% CI 0.73-0.98) in the overall population and a larger absolute benefit in the pre-specified subgroup with baseline LDL-C at or above 100 mg/dL [2]. The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol states: "In patients with very high-risk ASCVD who are on maximally tolerated statin therapy and whose LDL-C remains 70 mg/dL or higher, it is reasonable to add a PCSK9 inhibitor" (Class IIa, Level of Evidence A) [4].

That guideline language is the clinical backbone of nearly every prior authorization form a DC prescriber will complete for Praluent. Insurers read "Class IIa, Level A" and require documentation that the patient has tried and tolerated the highest statin dose before approving a $580/month biologic.

The ODYSSEY LONG TERM trial (N=2,341, 78-week duration) showed alirocumab 150 mg Q2W reduced LDL-C by 61% from baseline versus placebo, with a consistent safety profile [5]. Injection-site reactions occurred in 7.2% of alirocumab patients versus 5.1% of placebo patients, and no meaningful excess of neurocognitive adverse events appeared [5].

Praluent Cash Price in DC in 2026

The retail cash price for Praluent in District of Columbia pharmacies sits at approximately $580 per month in 2026. That is the price a patient without insurance or without an active manufacturer savings card would pay at a standard retail pharmacy such as CVS, Walgreens, or a local independent.

GoodRx and similar coupon aggregators occasionally show slightly lower prices for specific DC zip codes, but discounts on branded biologics remain modest compared to generic small molecules. A patient paying entirely out of pocket for 24 injections per year (two per month) would spend roughly $6,960 annually at list price.

No generic alirocumab is FDA-approved as of early 2026. Biosimilars for PCSK9 inhibitors have not yet completed the regulatory pathway in the United States, though the space is being watched closely given the patent situation [6]. Until a biosimilar launches, the cash market for branded Praluent reflects full WAC minus any pharmacy-negotiated discounts, which are small.

Patients who cannot use the manufacturer card and do not qualify for Medicaid should ask their cardiologist or primary care provider to document the full prior authorization rationale and appeal any commercial denial, since denial rates for PCSK9 inhibitors have been estimated at 50-80% on first submission in some health systems [7].

DC Medicaid Coverage for Alirocumab

DC Medicaid covers Praluent, but prior authorization is required. The program applies to adults with a confirmed diagnosis of heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who meet specific LDL thresholds despite documented maximally tolerated statin therapy [8].

Typical PA criteria under DC Medicaid in 2026 include:

• Diagnosis of HeFH (confirmed by clinical criteria such as a Dutch Lipid Clinic Network score of 6 or higher, or genetic testing) OR established ASCVD (prior MI, stroke, or symptomatic peripheral artery disease)
• Current or recent use of a high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) at the maximally tolerated dose
• LDL-C remaining at or above 70 mg/dL (for ASCVD) or 100 mg/dL (for primary prevention HeFH without ASCVD) despite statin therapy
• Documentation of statin intolerance if a lower-intensity statin is prescribed

DC Medicaid does not apply a quantity limit beyond the labeled twice-monthly dosing schedule. Initial PA approvals are generally granted for 12 months, after which renewal requires documentation that LDL-C has responded and the patient remains at high CV risk [8].

The District of Columbia follows the federal Medicaid drug rebate program, which means Regeneron and Sanofi pay a statutory rebate back to DC Medicaid, effectively reducing the program's net cost below the $580 WAC. Patients covered by DC Medicaid typically pay no copay for Praluent if the PA is approved.

Prescribers submitting a PA for a DC Medicaid patient should reference the ODYSSEY OUTCOMES hazard ratio data [2] and the ACC/AHA Class IIa recommendation [4] directly in the PA justification letter, as these are the two evidence elements DC Medicaid reviewers weigh most heavily.

Commercial Insurance Coverage in DC

Most commercial plans sold on the DC Health Link exchange and employer-sponsored plans operating in DC cover alirocumab under the specialty tier with PA requirements mirroring those of DC Medicaid. The main differences are cost-sharing structure and the availability of the manufacturer savings card to offset patient out-of-pocket costs.

Step therapy is common. Insurers may require documented trials of two or more statins, ezetimibe 10 mg, and in some cases bile acid sequestrants before approving a PCSK9 inhibitor. The ACC/AHA 2022 guideline explicitly supports ezetimibe as a second-line agent before PCSK9 inhibitors [4], so step therapy aligning with those guidelines is considered clinically consistent, if financially frustrating for patients with very high baseline LDL-C.

A 2020 analysis in the Journal of the American College of Cardiology estimated that only 40% of patients who met guideline criteria for PCSK9 inhibitor therapy successfully obtained coverage within 90 days of prescription submission, due to PA complexity and step therapy requirements [7]. DC-specific denial rates are not published separately, but the national pattern applies.

Appeals succeed more often when the prescriber provides:

1. A completed lipid panel dated within 90 days showing persistent LDL elevation
2. Notes documenting statin-associated muscle symptoms or other intolerance, if applicable
3. A cardiovascular risk summary citing ASCVD event history or FH score
4. Direct quotation of the ACC/AHA Class IIa, Level A recommendation [4]

The FDA label for Praluent is publicly accessible at the FDA accessdata portal and can be attached to appeal letters to confirm the labeled indication [1].

Compounded Alirocumab in DC: What 503A Means

Compounded alirocumab is available in the District of Columbia through 503A pharmacies operating under state (DC) pharmacy board licensure. This is a separate regulatory category from FDA-approved Praluent, and the two are not interchangeable in the regulatory sense.

503A pharmacies compound drugs for individual patients based on a valid prescription from a licensed provider. They are not subject to FDA approval requirements but must comply with USP standards and DC Board of Pharmacy regulations [9]. The compounded product may use alirocumab active pharmaceutical ingredient (API) sourced from qualified suppliers, but the final compound has not undergone the clinical trials that the branded product completed.

A practical decision framework for DC providers and patients considering compounded alirocumab:

Use branded Praluent when:

• The patient has commercial insurance with an active manufacturer savings card reducing copay to $0 or near $0
• DC Medicaid has approved the PA (no cost to patient)
• The patient's insurer will cover only the FDA-approved biologic

Consider 503A compounded alirocumab when:

• The patient is uninsured or underinsured and cannot access the manufacturer card (for example, Medicare beneficiaries, who are ineligible for commercial manufacturer savings programs)
• The branded product has been denied after a first and second appeal
• The prescribing provider has a clinical relationship with a licensed DC 503A pharmacy that can document API source and sterility testing

The cash price for compounded alirocumab through specific 503A programs can be substantially lower than $580/month, and some programs list it at no direct patient cost, though the specifics depend on the individual pharmacy and any associated clinical program. Providers should obtain a certificate of analysis for the compounded product and document informed consent covering the non-FDA-approved status of the compound [9].

Compounded biologics raise additional questions about immunogenicity that do not apply to small-molecule compounds. No published RCT has evaluated the safety or efficacy of compounded alirocumab head-to-head with branded Praluent. Patients choosing this route should have baseline and follow-up LDL panels at 4 and 8 weeks to confirm response, consistent with the FDA label monitoring schedule [1].

Telehealth Prescribing of Praluent in DC

Praluent can be prescribed via telehealth in the District of Columbia. DC law permits licensed physicians, nurse practitioners, and physician assistants to prescribe Schedule-unscheduled medications (alirocumab is not a controlled substance) after a synchronous audio-video encounter that meets DC Board of Medicine standards for establishing a patient-provider relationship [10].

Telehealth prescribing is well-suited to PCSK9 inhibitor management because the key clinical decision points are laboratory-based. LDL-C, a lipid panel, and CMP can be ordered through any local DC lab draw site or patient service center. The prescriber reviews results asynchronously, adjusts the dose from 75 mg to 150 mg Q2W if needed, and handles prior authorization paperwork digitally.

HealthRX telehealth providers licensed in DC follow a protocol requiring at minimum one lipid panel before prescribing, documentation of current statin therapy or intolerance, and repeat LDL-C at 8 weeks post-initiation. This mirrors the monitoring schedule in the Praluent FDA label [1] and aligns with ACC/AHA guidance [4].

Telehealth visits cannot waive the prior authorization process for insured patients. The provider must still complete the PA form and submit clinical documentation to the insurer. However, telehealth platforms often have dedicated PA support staff who can reduce the administrative burden on the patient.

Manufacturer Savings Card: How the Regeneron/Sanofi Program Works in DC

Regeneron and Sanofi offer a copay savings program for commercially insured patients in DC. Eligible patients can pay as little as $0 per month for Praluent, depending on their plan's coverage tier. The card covers the difference between the patient's copay or coinsurance and the program cap.

Eligibility requirements for the manufacturer savings card:

• Patient must have commercial insurance (employer-sponsored or marketplace plan). Medicare Part D, Medicaid, and other federal program beneficiaries are explicitly excluded [11].
• The drug must be covered under the patient's commercial plan, even if subject to a high specialist copay or coinsurance
• Patient must reside in the United States (DC qualifies)
• Income limits do not apply to the copay card itself, unlike the patient assistance program

For uninsured patients or those excluded from the copay card, Regeneron and Sanofi operate a separate patient assistance program (PAP) that may provide Praluent at no cost for patients meeting income eligibility thresholds. Income cutoffs and enrollment procedures for the PAP are managed directly through the manufacturer and change periodically; prescribers should refer patients to the official Praluent support line (listed on the FDA-registered prescribing information document) or to a pharmacist for current thresholds [11].

Medicare Part D beneficiaries with high LDL-C or ASCVD who cannot access the manufacturer card face the starkest cost burden. In that situation, the DC Medicaid Qualified Medicare Beneficiary (QMB) program may cover Part D cost-sharing for dual-eligible patients, and a 503A compounded alternative becomes a more serious clinical conversation [8].

LDL Goals and Dose Selection: Clinical Context for DC Providers

The ACC/AHA 2022 guideline recommends an LDL-C goal of less than 70 mg/dL for patients with established ASCVD and less than 55 mg/dL for very-high-risk ASCVD (defined as two or more major ASCVD events or one major event plus multiple high-risk conditions) [4]. For HeFH without ASCVD, the target is less than 100 mg/dL.

Alirocumab 75 mg Q2W reduces LDL-C by approximately 44-50% from baseline when added to a statin. The 150 mg Q2W dose achieves reductions of 54-61% [3, 5]. Prescribers should start most patients at 75 mg Q2W and measure LDL-C at 4-8 weeks. If the goal is not reached, titrate to 150 mg Q2W and recheck at another 4-8 weeks [1].

A 2021 analysis of real-world PCSK9 inhibitor use found that patients who achieved LDL-C below 55 mg/dL had a 24% lower rate of recurrent ASCVD events compared to patients who achieved 55-70 mg/dL, reinforcing the value of aggressive titration [12]. DC prescribers writing the 150 mg dose should note that the list price remains the same as the 75 mg dose, so there is no cost penalty for titrating up.

Adverse effects of alirocumab are generally mild. Injection-site reactions occur in approximately 7% of patients [5]. Nasopharyngitis, influenza-like illness, and urinary tract infections appeared at slightly higher rates in alirocumab arms across ODYSSEY trials but were not statistically significant versus placebo [2, 5]. The long-term neurocognitive signal that generated early concern has not materialized in post-marketing surveillance or in the ODYSSEY OUTCOMES analysis [2].

Navigating the PA Process as a DC Patient

Prior authorization for Praluent in DC typically takes 3-14 business days from the date of submission. Commercial insurers are required under DC law (the DC Insurance Reform Amendment Act of 2022) to respond to non-urgent PA requests within 72 hours and urgent requests within 24 hours, though complex specialty PA reviews sometimes extend beyond these windows pending clinical documentation receipt.

Steps that reduce denial risk:

1. Have your provider obtain a fasting lipid panel dated within 90 days before submitting the PA. LDL-C must be clearly documented.
2. Confirm in the chart that you are on maximally tolerated statin therapy. If you are statin-intolerant, the chart must document a trial of at least two statins with recorded adverse effects.
3. Ask your provider to include the ODYSSEY OUTCOMES hazard ratio citation [2] and the ACC/AHA Class IIa recommendation [4] in the clinical justification section of the PA form.
4. Request expedited review if you have had a cardiac event within the past 12 months, citing the ODYSSEY OUTCOMES subgroup data showing the largest absolute benefit in the highest-risk patients [2].

If the first PA is denied, a peer-to-peer review call between your prescribing cardiologist or internist and the insurer's medical director resolves a meaningful proportion of cases. Peer-to-peer calls are available as a right under DC insurance regulations and should be requested within the appeal window [10].

Familial Hypercholesterolemia: Why Diagnosis Changes the Cost Equation

Patients with confirmed HeFH represent a distinct subgroup where payers apply somewhat different criteria. HeFH affects approximately 1 in 250 adults in the general population, though diagnosis rates remain low [13]. In confirmed HeFH, statins alone rarely bring LDL-C to guideline targets because the genetic defect impairs LDL receptor function at baseline.

The FDA label specifically names HeFH as a primary indication for alirocumab [1]. A genetic diagnosis (pathogenic variant in LDLR, APOB, or PCSK9 confirmed by sequencing) or a Dutch Lipid Clinic Network score of 6 or higher typically satisfies the diagnostic criterion in DC Medicaid and most commercial PA forms without requiring a documented statin failure trial, since the clinical expectation of statin-only response is lower.

In ODYSSEY FH I and FH II (combined N=735), alirocumab 75-150 mg Q2W reduced LDL-C by 57.9% from baseline versus a 0.5% increase with placebo at 24 weeks (P<0.001) [14]. That magnitude of reduction translates to a meaningful proportion of HeFH patients reaching LDL-C below 100 mg/dL for the first time.

DC patients with suspected HeFH who have not yet received genetic testing can pursue testing through several academic medical center lipid programs in the Washington, DC area, which may strengthen the PA documentation considerably.

Comparing Alirocumab with Evolocumab in DC

Evolocumab (Repatha, Amgen) is the only other FDA-approved PCSK9 inhibitor as of early 2026. Its WAC is also approximately $500-600 per month. In head-to-head LDL-lowering comparisons, the two drugs perform similarly at their respective maximum doses [3]. DC Medicaid and most commercial plans in DC cover both agents, and some formularies prefer one over the other based on negotiated rebates.

When Praluent is denied or formulary-restricted, prescribers can attempt a formulary exception for Praluent or simply prescribe evolocumab as the preferred alternative. The cardiovascular outcomes trial for evolocumab (FOURIER, NEJM 2017, N=27,564) showed a 15% reduction in the composite primary endpoint versus placebo (HR 0.85, P<0.001), nearly identical to ODYSSEY OUTCOMES [15].

Patients and providers in DC who face repeated Praluent denials should ask the insurer directly whether evolocumab is on the preferred specialty tier, since substituting the preferred PCSK9 inhibitor is often faster than appealing a non-preferred one.

Summary of 2026 Cost Scenarios for DC Patients

Rather than listing abstract options, the following concrete scenarios reflect the actual paths available in DC in 2026:

Scenario A: Commercially insured DC patient with ASCVD, PA approved, manufacturer card active. Monthly out-of-pocket cost: $0/month. Annual cost to patient: $0.

Scenario B: DC Medicaid patient with HeFH, PA approved. Monthly out-of-pocket cost: $0/month. Annual cost to patient: $0.

Scenario C: Commercially insured, PA denied after appeal, no card eligibility. Options include 503A compounded alirocumab or switching to the formulary-preferred PCSK9 inhibitor if available.

Scenario D: Medicare Part D patient, not dual-eligible. Full specialty tier cost-sharing applies; the manufacturer card is not available. 503A compounded alirocumab or formal PAP application through the manufacturer is the primary cost-reduction path.

Scenario E: Uninsured DC patient. Cash price approximately $580/month for branded Praluent. Manufacturer PAP may reduce this to $0 if income criteria are met. 503A compounded alirocumab is available as an alternative at substantially lower cost.

Patients in Scenarios C, D, or E should contact a HealthRX telehealth provider licensed in DC to discuss which pathway aligns with their clinical profile and financial situation. A baseline LDL-C and lipid panel ordered through a DC LabCorp or Quest draw site is the first concrete step regardless of which coverage path is pursued.